Cardinal Health, Inc.

NYSE:CAH Stock Report

Market Cap: US$28.3b

Cardinal Health Valuation

Is CAH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAH ($118.28) is trading below our estimate of fair value ($324.38)

Significantly Below Fair Value: CAH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAH?

Key metric: As CAH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CAH. This is calculated by dividing CAH's market cap by their current earnings.
What is CAH's PE Ratio?
PE Ratio22.4x
EarningsUS$1.28b
Market CapUS$28.32b

Price to Earnings Ratio vs Peers

How does CAH's PE Ratio compare to its peers?

The above table shows the PE ratio for CAH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
COR Cencora
29.2x14.8%US$43.7b
MCK McKesson
29x15.0%US$73.5b
HSIC Henry Schein
27.7x26.7%US$8.6b
PDCO Patterson Companies
17.6x13.0%US$2.7b
CAH Cardinal Health
22.4x7.4%US$28.3b

Price-To-Earnings vs Peers: CAH is good value based on its Price-To-Earnings Ratio (22.4x) compared to the peer average (25.9x).

Price to Earnings Ratio vs Industry

How does CAH's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
3.9x-39.2%US$11.95b
NEUE NeueHealth
1.1xn/aUS$32.60m
IDXG Interpace Biosciences
2.6xn/aUS$11.71m
FZMD Fuse Medical
2.2xn/aUS$8.67m
CAH 22.4xIndustry Avg. 21.9xNo. of Companies10PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CAH is expensive based on its Price-To-Earnings Ratio (22.4x) compared to the US Healthcare industry average (21.9x).

Price to Earnings Ratio vs Fair Ratio

What is CAH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.4x
Fair PE Ratio28.7x

Price-To-Earnings vs Fair Ratio: CAH is good value based on its Price-To-Earnings Ratio (22.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$118.28
US$129.74
+9.7%
8.7%US$149.00US$107.00n/a15
Dec ’25US$122.24
US$125.48
+2.7%
10.5%US$145.00US$101.00n/a15
Nov ’25US$116.13
US$121.02
+4.2%
10.4%US$145.00US$101.00n/a16
Oct ’25US$110.33
US$117.32
+6.3%
8.0%US$140.00US$101.00n/a16
Sep ’25US$112.72
US$115.57
+2.5%
8.2%US$137.00US$101.00n/a16
Aug ’25US$103.39
US$111.07
+7.4%
8.5%US$130.00US$92.00n/a16
Jul ’25US$97.76
US$112.01
+14.6%
8.1%US$129.00US$92.00n/a16
Jun ’25US$99.27
US$111.40
+12.2%
8.3%US$129.00US$92.00n/a15
May ’25US$102.17
US$112.31
+9.9%
9.4%US$134.00US$88.00n/a16
Apr ’25US$112.06
US$113.31
+1.1%
8.8%US$133.00US$93.00n/a16
Mar ’25US$113.37
US$113.31
-0.06%
8.8%US$133.00US$93.00n/a16
Feb ’25US$105.10
US$109.67
+4.3%
8.8%US$128.00US$93.00n/a15
Jan ’25US$100.80
US$106.50
+5.7%
8.3%US$126.00US$90.00n/a14
Dec ’24US$107.16
US$104.28
-2.7%
10.6%US$126.00US$78.70US$122.2413
Nov ’24US$93.58
US$95.59
+2.2%
9.2%US$110.00US$78.70US$116.1313
Oct ’24US$86.82
US$94.90
+9.3%
10.0%US$108.00US$78.00US$110.3313
Sep ’24US$87.58
US$96.08
+9.7%
8.5%US$108.00US$78.00US$112.7214
Aug ’24US$91.64
US$91.79
+0.2%
10.4%US$107.00US$67.00US$103.3914
Jul ’24US$94.57
US$89.61
-5.2%
9.5%US$103.00US$67.00US$97.7615
Jun ’24US$83.42
US$86.14
+3.3%
8.8%US$97.00US$67.00US$99.2715
May ’24US$82.25
US$84.53
+2.8%
9.1%US$97.00US$67.00US$102.1715
Apr ’24US$75.50
US$83.59
+10.7%
9.0%US$94.00US$67.00US$112.0615
Mar ’24US$75.98
US$84.42
+11.1%
8.7%US$94.00US$67.00US$113.3714
Feb ’24US$75.72
US$83.00
+9.6%
10.0%US$100.00US$67.00US$105.1014
Jan ’24US$76.87
US$79.71
+3.7%
7.5%US$90.00US$67.00US$100.8014
Dec ’23US$79.26
US$79.31
+0.06%
7.6%US$90.00US$67.00US$107.1613

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cardinal Health, Inc. is covered by 40 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird